clonidine
Commercial- Indications
- Hypertension
Company intelligence / Profile preview
NextWave Pharmaceuticals
Cupertino, California, United Statesnextwavepharma.com ↗
- Ownership
- Private
- Employees
- ~75
- Development stage
- Commercial
01
Overview
NextWave Pharmaceuticals developed unique extended-release liquid and chewable formulations for CNS indications. Its lead product, Quillivant XR™—the first once-daily liquid methylphenidate for ADHD—was FDA-approved in 2012. The company also commercialized Nexiclon XR for hypertension. After its acquisition by Pfizer in 2012, key ADHD assets were later acquired by Tris Pharma in 2018.
- Therapeutic areas
- PsychiatryCardiovascularNeurology
- Modalities
- Small moleculesExtended-release formulations
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Tris Pharma – co-development/manufacturing partner using proprietary OralXR+/LiquiXR platforms.
Beyond the preview
Go deeper on NextWave Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NextWave Pharmaceuticals.